BR112020012589 composto, composição farmacêutica, métodos para inibir sinalização de par2 e para prevenir ou tratar uma doença ou distúrbio mediado por sinalização de par2, e, uso de um composto.

Settings

Stemming

Single Family Member

Include NPL

Feedback

Goto Application

National Biblio. Data
Patent Family

Office

Brazil

Application Number 112020012589

Application Date 19.12.2018

Publication Number 112020012589

Publication Date 24.11.2020

Publication Kind A2

IPC

CPC

View more classifications

View less classifications

Applicants TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventors BERNARD LUKE FLYNN
LE GIANG
LUIGI AURELIO
NIGEL BUNNETT

Agents KASZNAR LEONARDOS PROPRIEDADE INTELECTUAL

Priority Data 2017905084 20.12.2017 AU

Title

(PT) composto, composição farmacêutica, métodos para inibir sinalização de par2 e para prevenir ou tratar uma doença ou distúrbio mediado por sinalização de par2, e, uso de um composto.

Abstract

(PT) a presente invenção refere-se geralmente a compostos capazes de inibir o receptor ativado por protease-2 (par2) e usos dos mesmos. mais especificamente, a presente invenção refere-se a inibidores de par2, à sua preparação e ao seu uso no tratamento de doenças e distúrbios mediados pela sinalização de par2.

C	CHEMISTRY; METALLURGY
07	ORGANIC CHEMISTRY
D	HETEROCYCLIC COMPOUNDS
487	Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/-C07D477/183

A	HUMAN NECESSITIES
61	MEDICAL OR VETERINARY SCIENCE; HYGIENE
K	PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31	Medicinal preparations containing organic active ingredients

A	HUMAN NECESSITIES
61	MEDICAL OR VETERINARY SCIENCE; HYGIENE
P	SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25	Drugs for disorders of the nervous system

A	HUMAN NECESSITIES
61	MEDICAL OR VETERINARY SCIENCE; HYGIENE
P	SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
29	Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents; Non-steroidal antiinflammatory drugs (NSAIDs)

A	HUMAN NECESSITIES
61	MEDICAL OR VETERINARY SCIENCE; HYGIENE
P	SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35	Antineoplastic agents

Processing

National Phase Entries

Authority File

Settings

Feedback

Goto Application

1. BR112020012589 - composto, composição farmacêutica, métodos para inibir sinalização de par2 e para prevenir ou tratar uma doença ou distúrbio mediado por sinalização de par2, e, uso de um composto.

A	HUMAN NECESSITIES
61	MEDICAL OR VETERINARY SCIENCE; HYGIENE
K	PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47	Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50	the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51	the non-active ingredient being a modifying agent
62	the modifying agent being a protein, peptide or polyamino acid
65	Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers

A	HUMAN NECESSITIES
61	MEDICAL OR VETERINARY SCIENCE; HYGIENE
K	PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47	Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50	the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51	the non-active ingredient being a modifying agent
62	the modifying agent being a protein, peptide or polyamino acid
65	Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers

C	CHEMISTRY; METALLURGY
07	ORGANIC CHEMISTRY
D	HETEROCYCLIC COMPOUNDS
235	Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
02	condensed with carbocyclic rings or ring systems